Cilnidipine ( DrugBank: Cilnidipine )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
67 | 多発性嚢胞腎 | 2 |
67. 多発性嚢胞腎
臨床試験数 : 216 / 薬物数 : 219 - (DrugBank : 50) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 151
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00890279 (ClinicalTrials.gov) | July 2009 | 28/4/2009 | Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD) | Phase II Study for the Second-Line Treatment of Hypertension in Patients With Autosomal Dominant Polycystic Kidney Disease; ACEI vs. CCB | Kidney, Polycystic, Autosomal Dominant | Drug: Cilnidipine;Drug: Imidapril | Ministry of Health, Labour and Welfare, Japan | NULL | Recruiting | 20 Years | 60 Years | Both | 160 | Phase 2 | Japan |
2 | NCT00541853 (ClinicalTrials.gov) | December 2007 | 9/10/2007 | CCB Safety Study in Treatment of Hypertension of ADPKD | Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients | Kidney, Polycystic, Autosomal Dominant | Drug: Candesartan;Drug: Candesartan and Cilnidipine;Drug: Candesartan plus non-CCB agents | Kyorin University | Ministry of Health, Labour and Welfare, Japan | Not yet recruiting | 20 Years | 60 Years | Both | 150 | Phase 4 | Japan |